Global Healthcare Market and Growth Strategy

Think Research Q2 Results $10.2 million Revenue for quarter Which was a beat vs. consensus of $9.5 million ↑167% Increase from Q2 2020 Rapid growth as Think scales up to meet rising demand $6.7 million Cash balance on June 30, 2021 Sufficient funds to complete BioPharma transaction $3 million In cost synergies realized during Q3 2021 Management executing to plan " We see significant growth ahead for THNK as it executes its strategy of building a unique hybrid healthcare delivery platform through acquisitions and strong organic growth in a large addressable market undergoing significant disruption on the back of the COVID-19 pandemic. -Desjardins Securities analyst David Newman told The Globe and Mail thinkresearch TSXV: THNK 18

View entire presentation